The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Open accessAbstract
Objectives To assess the safety and efficacy of interleukin (IL)−6 blockade with sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation. Methods We conducted an open-label study of sarilumab in severe COVID-19 pneumonia (PaO2/FiO2 <300 mm Hg) with hyperinflammation (elevated inflammatory markers and serum IL-6 levels). Sarilumab 400 mg was administered intravenously in addition to standard of care and results were compared with contemporary matched patients treated with standard of care alone. Clinical improvement, mortality, safety and predictors of response were assessed at 28 days. Results Twenty-eight patients were treated with sarilumab and 28 contemporary patients receiving standard of care alone were used as controls. At day 28 of follow-up, 61% of patients treated with sarilumab experienced clinical improvement and 7% died. These findings were not significantly different from the comparison group (clinical improvement 64%, mortality 18%; p=NS). Baseline PaO2/FiO2 ratio >100 mm Hg and lung consolidation <17% at CT scan predicted clinical improvement in patients treated with sarilumab. Median time to clinical improvement in patients with lung consolidation <17% was shorter after sarilumab (10 days) than after standard treatment (24 days; p=0.01). The rate of infection and pulmonary thrombosis was similar between the two groups. Conclusions At day 28, overall clinical improvement and mortality in patients with severe COVID-19 were not significantly different between sarilumab and standard of care. Sarilumab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State
Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., & Lee, M. (2020) · JAMA · doi:10.1001/jama.2020.4326 · Cited by 2,259
Coronavirus Disease 2019 (COVID-19): A Perspective from China
Zu, Z. Y., Jiang, M. D., Xu, P. P., Chen, W., Ni, Q. Q., Lu, G. M., & Zhang, L. J. (2020) · Radiology · doi:10.1148/radiol.2020200490 · Cited by 2,070 · cited 1×
“31 The results of ongoing randomised placebo-controlled trials on larger number of patients are eagerly awaited to possibly substantiate our findings.”
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045
Hypercytokinemia in familial hemophagocytic lymphohistiocytosis
Henter, J., Elinder, G., Soder, O., Hansson, M., Andersson, B., & Andersson, U. (1991) · Blood · doi:10.1182/blood.v78.11.2918.2918 · Cited by 505
Zangrillo, A., Beretta, L., Silvani, P., Colombo, S., Scandroglio, A. M., Dell’Acqua, A., Fominskiy, E., Landoni, G., Monti, G., Azzolini, M. L., et al. (2020) · Critical Care and Resuscitation · doi:10.51893/2020.2.pov1 · Cited by 221
Self-citationDe Luca, G., Cavalli, G., Campochiaro, C., Della-Torre, E., Angelillo, P., Tomelleri, A., Boffini, N., Tentori, S., Mette, F., Farina, N., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30170-3 · Cited by 202
Self-citation
Cited by
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Aging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
Aliyu, M., Zohora, F. T., Anka, A. U., Ali, K., Maleknia, S., Saffarioun, M., & Azizi, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109130 · Cited by 401
Szabo, P. A., Dogra, P., Gray, J. I., Wells, S. B., Connors, T. J., Weisberg, S. P., Krupska, I., Matsumoto, R., Poon, M. M. L., Idzikowski, E., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.005 · Cited by 383
Metadata
- Authors
- Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Napolitano, A., La Marca, S., Boffini, N., Da Prat, V., Di Terlizzi, G., Lanzillotta, M., Rovere Querini, P., Ruggeri, A., Landoni, G., Tresoldi, M., Ciceri, F., Zangrillo, A., De Cobelli, F., & Dagna, L.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 79
- Issue
- 10
- Pages
- 1277-1285
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W3038241707
- Cited by
- 236
- References
- 8
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. https://app.cochat.ai/papers/10.1136/annrheumdis-2020-218122
- The paper
- Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Napolitano, A., La Marca, S., Boffini, N., Da Prat, V., Di Terlizzi, G., Lanzillotta, M., Rovere Querini, P., Ruggeri, A., Landoni, G., Tresoldi, M., Ciceri, F., Zangrillo, A., De Cobelli, F., & Dagna, L. (2020). Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2020-218122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.